Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02848079 · ClinicalTrials.gov registry record · Phase 1
TAS-OX for Refractory Metastatic Colon Cancer
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT02848079 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 41 participants.
The verdict
NCT02848079, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
This study will examine the safety and effectiveness of oxaliplatin in combination with TAS-102 (TAS-OX) for treatment of patients with metastatic colorectal cancer whose cancer has progressed or recurred after FOLFOX chemotherapy.
Interventions
- DRUG combined TAS-102 and TAS-OX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2016-10-31 |
| Est. Completion | 2020-06-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02848079
The ClinicalTrials.gov registry entry for NCT02848079 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which combined TAS-102 and TAS-OX is the first listed.
NCT02848079 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02848079 about?
NCT02848079 is a clinical study titled "TAS-OX for Refractory Metastatic Colon Cancer". This study will examine the safety and effectiveness of oxaliplatin in combination with TAS-102 (TAS-OX) for treatment of patients with metastatic colorectal cancer whose cancer has progressed or recurred after FOLFOX chemotherapy.
What is the current status of trial NCT02848079?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2016-10-31. Estimated completion is 2020-06-02.
What interventions are being tested in trial NCT02848079?
The interventions under investigation include: combined TAS-102 and TAS-OX (DRUG).
Who is sponsoring clinical trial NCT02848079?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.